AstraZeneca Launches $50B U.S. CRE Expansion With Virginia GLP-1 Manufacturing Facility

Another pharmaceutical giant is planning to spend billions on its U.S. footprint amid the Trump administration’s domestic manufacturing push.

AstraZeneca's facility in Rockville, Maryland.
Bisnow/Emily Wishingrad
An Astrazeneca Facility In Rockville, Maryland

AstraZeneca intends to spend $50B on expansion across the nation by 2030, according to a Monday press release.

A large share of that will go to a Virginia manufacturing facility focused on the company’s weight-loss drugs, including the GLP-1 pills.

The upcoming factory will be AstraZeneca’s largest investment in a single manufacturing property and will be a high-tech facility with artificial intelligence, automation and data analytics, the release says.

AstraZeneca will also build or expand research and development facilities outside Washington, D.C., and Baltimore and manufacturing facilities in Texas, Indiana and California.

This is in addition to the company’s pledge to invest $3.5B in its U.S. footprint, made days after President Donald Trump was elected in November. The first wave of that expansion, an 85K SF manufacturing facility in Montgomery County, Maryland, opened in May.

Commerce Secretary Howard Lutnick praised the announcement.

“For decades Americans have been reliant on foreign supply of key pharmaceutical products,” he said in a statement. “This historic investment is bringing tens of thousands of jobs to the US and will ensure medicine sold in our country is produced right here.”

Other Big Pharma companies announced similar investments in recent months. In the first five months of 2025, firms including Roche, Eli Lilly and Johnson & Johnson committed to investing nearly $160B across the U.S.

Trump is considering tariffs that could have a massive impact on the pharmaceutical industry. Earlier this month, he suggested that there could be a levy of up to 200% on imported drugs following a 12-to-18-month grace period to allow for onshoring, CNBC reported.

The president also signed a May executive order seeking to lower the cost of certain drugs by tethering them to the price patients pay abroad.

Continue reading this story with a free account

Log in or register
Sign up for more articles like this
Subscribe to Bisnow's National Newsletters
Related Stories

The Blue Wave Has Foreign Capital Dipping Its Toes Back Into U.S. Commercial Real Estate

HUD Issues Final Citizenship Rule, Giving Landlords Just Weeks To Comply

Philly Life Sciences Players Say Sluggish Market Needs More VC, State Funding

Meta's Soaring Data Center Emissions Force It To Reconsider Climate Goal

The Children's Place Hires Adviser To Sell 509 Store Leases, Distribution Center

Senate Passes Bill To Speed Up Permitting, Make Data Centers Pay More

Trepp: 20% Of The CMBS Loans Modified Since 2022 Are Delinquent Again

INSIDE THE SPACE: A Luxury Salon Suite Concept Expands Nationally

Anthropic's Record IPO Reverberates Across Data Center Sector

Brookfield's Lowell Baron On Building The Firm's Edge, Where It's Betting Next

Brookfield Bets $110M On Resorts Company Rolling Up Independent Campgrounds

KFC Operator Is Latest Casualty In Wave Of Fast-Food Franchisee Bankruptcies